- Shares of United Therapeutics ( NASDAQ: UTHR ) reached an all-time high Wednesday of $244.80.
- Year to date, the stock is up ~15% .
- United Therapeutics ( UTHR ) was buoyed by the May U.S. FDA approval of Tyvaso DPI (treprostinil) for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
- The company is also developing genetically engineered pig kidneys and hearts for human transplant.
- The FDA is preparing to allow clinical studies examining the transplantation of pig organs into humans, according to a recent report .
For further details see:
United Therapeutics reaches all-time high; shares up 15% YTD